Protara Therapeutics (TARA) News Today $3.48 +0.06 (+1.75%) As of 05/20/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TARA Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Janus Henderson Group PLC Invests $11.94 Million in Protara Therapeutics, Inc. (NASDAQ:TARA)Janus Henderson Group PLC bought a new position in Protara Therapeutics, Inc. (NASDAQ:TARA - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 2,271,832 shares of the company'sMay 19 at 4:35 AM | marketbeat.comWith 73% ownership, Protara Therapeutics, Inc. (NASDAQ:TARA) boasts of strong institutional backingMay 16, 2025 | finance.yahoo.comIntegral Health Asset Management LLC Makes New $7.39 Million Investment in Protara Therapeutics, Inc. (NASDAQ:TARA)Integral Health Asset Management LLC acquired a new position in Protara Therapeutics, Inc. (NASDAQ:TARA - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 1,400,000 shares of the company's stock, valued at approximately $7,392,00May 14, 2025 | marketbeat.comJ. Goldman & Co LP Takes $748,000 Position in Protara Therapeutics, Inc. (NASDAQ:TARA)J. Goldman & Co LP purchased a new stake in shares of Protara Therapeutics, Inc. (NASDAQ:TARA - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 141,748 shares of theMay 14, 2025 | marketbeat.comProtara Therapeutics to Participate in Upcoming Investor ConferencesMay 13, 2025 | globenewswire.comDriehaus Capital Management LLC Makes New Investment in Protara Therapeutics, Inc. (NASDAQ:TARA)Driehaus Capital Management LLC acquired a new stake in Protara Therapeutics, Inc. (NASDAQ:TARA - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 517,152 shares of the companMay 12, 2025 | marketbeat.comProtara Therapeutics, Inc. (NASDAQ:TARA) Receives Average Rating of "Buy" from BrokeragesProtara Therapeutics, Inc. (NASDAQ:TARA - Get Free Report) has received a consensus recommendation of "Buy" from the six brokerages that are presently covering the company, MarketBeat reports. Six research analysts have rated the stock with a buy rating. The average 1-year price target among brokeMay 12, 2025 | marketbeat.comBarclays PLC Takes $492,000 Position in Protara Therapeutics, Inc. (NASDAQ:TARA)Barclays PLC bought a new position in Protara Therapeutics, Inc. (NASDAQ:TARA - Free Report) in the 4th quarter, according to its most recent disclosure with the SEC. The firm bought 93,239 shares of the company's stock, valued at approximately $492,000. Barclays PLC owned 0.45% of Protara TherapeuMay 11, 2025 | marketbeat.comProtara Therapeutics, Inc. (NASDAQ:TARA) Given Average Rating of "Buy" by BrokeragesMay 11, 2025 | americanbankingnews.comProtara Therapeutics Reports Q1 2025 Financial ResultsMay 11, 2025 | tipranks.comProtara Therapeutics Announces First Quarter 2025 Financial Results and Provides Business UpdateMay 8, 2025 | globenewswire.comBlackstone Inc. Purchases Shares of 1,680,000 Protara Therapeutics, Inc. (NASDAQ:TARA)Blackstone Inc. acquired a new position in Protara Therapeutics, Inc. (NASDAQ:TARA - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The firm acquired 1,680,000 shares of the company's stock, valued at approximately $8,870,000. Blackstone Inc. owned 8.1May 8, 2025 | marketbeat.com5AM Venture Management LLC Takes Position in Protara Therapeutics, Inc. (NASDAQ:TARA)5AM Venture Management LLC acquired a new stake in Protara Therapeutics, Inc. (NASDAQ:TARA - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 800,000 shares of the company's stock, valued at approximatMay 4, 2025 | marketbeat.comAcorn Capital Advisors LLC Makes New Investment in Protara Therapeutics, Inc. (NASDAQ:TARA)Acorn Capital Advisors LLC bought a new stake in Protara Therapeutics, Inc. (NASDAQ:TARA - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 1,279,800 shares of the compaMay 4, 2025 | marketbeat.comRenaissance Technologies LLC Sells 194,440 Shares of Protara Therapeutics, Inc. (NASDAQ:TARA)Renaissance Technologies LLC reduced its position in shares of Protara Therapeutics, Inc. (NASDAQ:TARA - Free Report) by 57.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 142,300 shares of the companMay 4, 2025 | marketbeat.comRA Capital Management L.P. Buys 1,500,000 Shares of Protara Therapeutics, Inc. (NASDAQ:TARA)RA Capital Management L.P. boosted its position in Protara Therapeutics, Inc. (NASDAQ:TARA - Free Report) by 78.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,400,000 shares of the company's stock afterMay 3, 2025 | marketbeat.comBoothbay Fund Management LLC Has $470,000 Holdings in Protara Therapeutics, Inc. (NASDAQ:TARA)Boothbay Fund Management LLC increased its stake in shares of Protara Therapeutics, Inc. (NASDAQ:TARA - Free Report) by 411.2% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 88,941 shares of the company's stock after acquiring an additionaMay 3, 2025 | marketbeat.comProtara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 1, 2025 | globenewswire.comHC Wainwright Reiterates Buy Rating for Protara Therapeutics (NASDAQ:TARA)HC Wainwright restated a "buy" rating and set a $23.00 price objective on shares of Protara Therapeutics in a research report on Monday.April 30, 2025 | marketbeat.comAdage Capital Partners GP L.L.C. Buys Shares of 2,250,000 Protara Therapeutics, Inc. (NASDAQ:TARA)Adage Capital Partners GP L.L.C. bought a new stake in Protara Therapeutics, Inc. (NASDAQ:TARA - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 2,250,000 shares of the company's stock, valued at approximately $11April 30, 2025 | marketbeat.comProtara Therapeutics stock drops following interim trial resultsApril 29, 2025 | investing.comProtara Therapeutics stock drops following interim trial resultsApril 29, 2025 | investing.comProtara Therapeutics Announces Positive Interim Results Demonstrating Durable Responses in the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBCApril 26, 2025 | globenewswire.comProtara Therapeutics (TARA) to Release Quarterly Earnings on ThursdayProtara Therapeutics (NASDAQ:TARA) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 1. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-1-protara-therapeutics-inc-stock/)April 26, 2025 | marketbeat.comProtara Therapeutics to Host Conference Call and Webcast to Review Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Monday, April 28, 2025April 23, 2025 | globenewswire.comWalleye Capital LLC Takes $1.17 Million Position in Protara Therapeutics, Inc. (NASDAQ:TARA)Walleye Capital LLC purchased a new position in Protara Therapeutics, Inc. (NASDAQ:TARA - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 220,814 shares of the company's stock, valued at approximately $1April 22, 2025 | marketbeat.comProtara Therapeutics, Inc. (NASDAQ:TARA) Given Average Recommendation of "Buy" by AnalystsProtara Therapeutics, Inc. (NASDAQ:TARA - Get Free Report) has been given an average recommendation of "Buy" by the five brokerages that are presently covering the stock, Marketbeat Ratings reports. Five research analysts have rated the stock with a buy recommendation. The average 12-month targetApril 18, 2025 | marketbeat.comProtara Therapeutics (NASDAQ:TARA) Now Covered by Analysts at ScotiabankScotiabank initiated coverage on Protara Therapeutics in a report on Wednesday. They set a "sector outperform" rating and a $12.00 target price on the stock.April 18, 2025 | marketbeat.comProtara Therapeutics appoints Leonardo Viana Nicacio as chief medical officerApril 17, 2025 | markets.businessinsider.comProtara Therapeutics initiated with an Outperform at ScotiabankApril 17, 2025 | markets.businessinsider.comScotiabank Initiates Coverage of Protara Therapeutics (TARA) with Sector Outperform RecommendationApril 17, 2025 | msn.comProtara Therapeutics Announces Appointment of Leonardo Viana Nicacio, M.D., as Chief Medical OfficerApril 15, 2025 | globenewswire.comProtara Therapeutics to Present Interim Analysis from the Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the American Urological Association Annual MeetingApril 10, 2025 | globenewswire.comADAR1 Capital Management LLC Makes New Investment in Protara Therapeutics, Inc. (NASDAQ:TARA)ADAR1 Capital Management LLC bought a new position in shares of Protara Therapeutics, Inc. (NASDAQ:TARA - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 122,690 shares of the company's stock,April 9, 2025 | marketbeat.comProtara Therapeutics, Inc. (NASDAQ:TARA) Sees Large Drop in Short InterestProtara Therapeutics, Inc. (NASDAQ:TARA - Get Free Report) was the recipient of a significant decrease in short interest in the month of March. As of March 15th, there was short interest totalling 1,780,000 shares, a decrease of 40.1% from the February 28th total of 2,970,000 shares. Approximately 9.9% of the shares of the company are short sold. Based on an average trading volume of 347,300 shares, the days-to-cover ratio is presently 5.1 days.March 30, 2025 | marketbeat.comJacqueline Zummo Sells 21,224 Shares of Protara Therapeutics, Inc. (NASDAQ:TARA) StockProtara Therapeutics, Inc. (NASDAQ:TARA - Get Free Report) insider Jacqueline Zummo sold 21,224 shares of the stock in a transaction on Wednesday, March 26th. The shares were sold at an average price of $4.53, for a total value of $96,144.72. Following the sale, the insider now owns 98,861 shares in the company, valued at approximately $447,840.33. This represents a 17.67 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.March 29, 2025 | marketbeat.comProtara Therapeutics: Speculative Buy On Promising TARA-002 Trial ResultsMarch 28, 2025 | seekingalpha.comBladder Cancer Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and CompaniesMarch 26, 2025 | theglobeandmail.comCantor Fitzgerald Brokers Lower Earnings Estimates for TARAProtara Therapeutics, Inc. (NASDAQ:TARA - Free Report) - Analysts at Cantor Fitzgerald cut their FY2025 earnings per share estimates for shares of Protara Therapeutics in a note issued to investors on Thursday, March 20th. Cantor Fitzgerald analyst L. Watsek now anticipates that the company willMarch 24, 2025 | marketbeat.comProtara reveals choline deficiency in parenteral support patientsMarch 21, 2025 | uk.investing.comProtara Therapeutics announces presentation of results from THRIVE-1 studyMarch 21, 2025 | markets.businessinsider.comCantor Fitzgerald Estimates TARA FY2025 EarningsProtara Therapeutics, Inc. (NASDAQ:TARA - Free Report) - Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of Protara Therapeutics in a research note issued on Monday, March 17th. Cantor Fitzgerald analyst L. Watsek anticipates that the company will earn ($1.62)March 20, 2025 | marketbeat.comProtara Therapeutics Announces Encore Presentation of Results from THRIVE-1 Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral SupportMarch 19, 2025 | globenewswire.comProtara Therapeutics, Inc. (NASDAQ:TARA) Short Interest UpdateProtara Therapeutics, Inc. (NASDAQ:TARA - Get Free Report) saw a significant drop in short interest in the month of February. As of February 28th, there was short interest totalling 2,970,000 shares, a drop of 28.4% from the February 13th total of 4,150,000 shares. Based on an average daily volume of 2,310,000 shares, the days-to-cover ratio is presently 1.3 days. Approximately 16.5% of the shares of the company are sold short.March 17, 2025 | marketbeat.comProtara Therapeutics (TARA) Has a New Rating from LifeSci CapitalMarch 15, 2025 | markets.businessinsider.comProtara Therapeutics (NASDAQ:TARA) Coverage Initiated by Analysts at Cantor FitzgeraldCantor Fitzgerald assumed coverage on Protara Therapeutics in a research report on Friday. They set an "overweight" rating on the stock.March 15, 2025 | marketbeat.comCantor Fitzgerald Initiates Coverage of Protara Therapeutics (TARA) with Overweight RecommendationMarch 15, 2025 | msn.comProtara Therapeutics initiated with an Overweight at Cantor FitzgeraldMarch 14, 2025 | markets.businessinsider.comCantor starts Protara with Overweight, sees ‘multi-bagger potential’March 14, 2025 | markets.businessinsider.comAnalysts Issue Forecasts for TARA Q1 EarningsProtara Therapeutics, Inc. (NASDAQ:TARA - Free Report) - Analysts at Lifesci Capital issued their Q1 2025 earnings estimates for Protara Therapeutics in a research note issued to investors on Tuesday, March 11th. Lifesci Capital analyst C. Zhu expects that the company will earn ($0.37) per shareMarch 14, 2025 | marketbeat.com Get Protara Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TARA and its competitors with MarketBeat's FREE daily newsletter. Email Address TARA Media Mentions By Week TARA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TARA News Sentiment▼1.300.65▲Average Medical News Sentiment TARA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TARA Articles This Week▼42▲TARA Articles Average Week Get Protara Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TARA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies OPT News ETON News TYRA News RLAY News RGNX News ZVRA News UPB News AMLX News ARVN News DNA News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TARA) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredMan who predicted $100K Bitcoin sees a huge run coming for another coin …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protara Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protara Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TARA Stock Free TARA Stock Alerts